Mahesh patel lipocine
WebMar 24, 2024 · Lipocine ( NASDAQ: LPCN) is owned by 11.87% institutional shareholders, 10.71% Lipocine insiders, and 77.42% retail investors. Israel Menahem Vizel is the largest individual Lipocine shareholder, owning 3.00M shares representing 3.39% of the company. Israel Menahem Vizel's Lipocine shares are currently valued at $984.00k. WebDr. Mahesh Patel is a surgical oncologist specializing in the Abdomen and Thoracic cancer. Abdomen orGastro-Intestinal (GI) cancer is a term for the group of cancers that affect the …
Mahesh patel lipocine
Did you know?
WebDec 5, 2024 · This page shows the track record and history of Patel Mahesh V. insider trades in Lipocine Inc. The SEC defines Insiders as officers, directors, or significant … Webcorp.hiltonmanage.com
WebDec 19, 2024 · "We are excited to complete enrollment which leads to topline results mid-2024 for a serious end-stage condition with high unmet medical need," said Dr. Mahesh Patel, President and CEO of... WebSummary Presently, Mahesh V. Patel is President, Chief Executive & Financial Officer at Lipocine, Inc. He received an undergraduate degree from Karnataka University, a graduate degree from the University of Cincinnati (Ohio) and a doctorate from the University of Utah. Current positions of Mahesh V. Patel Holdings of Mahesh V. Patel
WebLipocine’s CEO is Mahesh Patel, appointed in Jan 1997, they has a tenure of 26.3yrs. Their total yearly compensation is US$883.9k, comprised of 55.9% salary and 44.1% bonuses, including company stock and options. They directly owns 1.9% of the company’s shares, worth US$537.0k. The average tenure of the management team and the board of ... WebMahesh V Patel is Chairman/Pres/CEO/Interim CFO/CO-Founder at Lipocine Inc. See Mahesh V Patel's compensation, career history, education, & memberships.
WebMar 25, 2024 · Lipocine Inc. (NASDAQ:LPCN – Get Rating) CEO Mahesh V. Patel acquired 150,000 shares of Lipocine stock in a transaction on Friday, March 24th. The shares were bought at an average price of $0.32 per share, for a total transaction of $48,000.00. Following the purchase, the chief executive officer now owns 1,678,090 …
WebApr 3, 2024 · The study is expected to enroll a total of 12 participants and is being conducted at a single center in the US. Results are expected in the first half of 2024. "We are excited about our development progress for LPCN 1154," said Dr. Mahesh Patel, President and CEO of Lipocine Inc. bsn4r3cd-a1806WebThe Orthopedic and Sports Medicine team at Watertown Regional Medical Center is led by board-certified and fellowship trained surgeons offering state-of-the-art technology and … exchange online delegate access powershellWeb1. Propofol (2,6-diisopropylphenol) is widely used as a general anesthetic and for the maintenance of long-term sedation. We have tested the hypothesis that propofol alters … bsn80s120WebSep 15, 2024 · Sep 15, 2024, 08:00 ET. FDA agrees with Lipocine establishing LPCN 1154 pathway to efficacy through a pharmacokinetic (PK) bridge to an approved IV infusion … exchange online definitionWebApr 14, 2024 · In other Lipocine news, CEO Mahesh V. Patel bought 150,000 shares of the firm’s stock in a transaction that occurred on Friday, March 24th. The stock was acquired … bsn76aWebAug 25, 2024 · Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine’s clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148, LPCN 1154, and LPCN 1107. bsn 72509-10 proshieldhttp://www.drmaheshpatel.com/ exchange online delegate mailbox access